Pharmaxis (PXS) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Pharmaxis Ltd Highlights Product Pipeline and RisksOctober 30, 2024 | markets.businessinsider.comSyntara bolsters financial position with R&D tax incentiveDecember 4, 2023 | proactiveinvestors.com.auHere's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More CloselyNovember 21, 2023 | finance.yahoo.comFIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slowsOctober 19, 2023 | proactiveinvestors.com.auPharmaxis to focus on clinical-stage drug developmentOctober 3, 2023 | proactiveinvestors.com.auPharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol businessOctober 3, 2023 | proactiveinvestors.com.auPharmaxis to Sell Mannitol Respiratory Business As Part of 'Major' RestructuringOctober 2, 2023 | marketwatch.comFIVE at FIVE AU: ASX gains as inflation easesAugust 30, 2023 | proactiveinvestors.com.auPharmaxis says majority of patients in fibrosis trial see significant improvementJuly 13, 2023 | finance.yahoo.comPXS.AX - Pharmaxis LtdJune 5, 2023 | finance.yahoo.comPharmaxis extends scarring collaboration after encouraging resultsMay 25, 2023 | proactiveinvestors.comPharmaxis achieves 30% reduction in scar tissue with topical LOX inhibitor in Phase 1C study; extends UWA collaborationMay 24, 2023 | proactiveinvestors.comPharmaxis Ltd (PXS.XA)May 21, 2023 | finance.yahoo.comPharmaxis adds combination treatment arm to Phase 2 myelofibrosis studyApril 11, 2023 | proactiveinvestors.com.auPharmaxis to accelerate plans for myelofibrosis combination study after FDA talksApril 11, 2023 | proactiveinvestors.comPharmaxis' PXS-5505 doubles response rate to standard therapy in blood cancer in preclinical studies; features in prestigious journalMarch 23, 2023 | proactiveinvestors.comPharmaxis Second Quarter 2023 Earnings: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)February 12, 2023 | finance.yahoo.comPharmaxis Ltd (PXS.AX)January 28, 2023 | nz.finance.yahoo.comPharmaxis strengthens board with appointment of experienced healthcare analyst Hashan De Silva as non-executive directorJanuary 15, 2023 | proactiveinvestors.comPharmaxis secures almost A$5 million in research and development tax incentivesJanuary 9, 2023 | proactiveinvestors.comPharmaxis' skin scarring study of its PXS-6302 asset now fully recruitedDecember 20, 2022 | proactiveinvestors.com.auPharmaxis appoints senior global pharma executive Dr Simon Green as a non-executive directorDecember 13, 2022 | proactiveinvestors.com.auPharmaxis cancer drug PXS-5505 profiled in two posters at American Society of Haematology ConferenceDecember 12, 2022 | proactiveinvestors.comPharmaxis receives interim data for Phase 2 cancer trialOctober 19, 2022 | proactiveinvestors.com.auPharmaxis welcomes positive interim data for Phase 2 cancer trialOctober 19, 2022 | proactiveinvestors.comLAST ORDERS: A light-hearted look at today’s market stuffOctober 18, 2022 | msn.comPharmaxis CEO talks promising interim data from skin scarring studySeptember 26, 2022 | proactiveinvestors.comPharmaxis fields promising interim data from skin scarring treatment study assessing PXS-6302September 25, 2022 | proactiveinvestors.comPXS.AX - Pharmaxis Ltd. | Stock Price & Latest News | ReutersSeptember 20, 2022 | reuters.comPharmaxis talks Parkinson's UK collaboration, A$5 million cash injectionSeptember 4, 2022 | proactiveinvestors.comASX Health Stocks: Pharmaxis gets $5m to fund groundbreaking collaboration study of lead drug PXS‐4728September 1, 2022 | msn.comProactive news headlines including Kinetiko Energy, Boadicea Resources, American Rare Earths and Surefire ResourcesSeptember 1, 2022 | yahoo.comPharmaxis to tackle Parkinson’s in “groundbreaking” clinical collaborationSeptember 1, 2022 | proactiveinvestors.comPharmaxis lands US$5 million deal with global drug delivery specialistAugust 5, 2022 | proactiveinvestors.comArovella Therapeutics bolsters management experience with appointment of non-executive directorJune 30, 2022 | proactiveinvestors.com.auPharmaxis appoints 20-year veteran as Chief Medical OfficerJune 30, 2022 | proactiveinvestors.comPharmaxis Ltd (ASX:PXS) insider upped their holding by 71% earlier this yearJune 6, 2022 | finance.yahoo.comGlobal Scar Treatment Market (2021 to 2029) - Share, Size, Trends and Industry Analysis ReportFebruary 24, 2022 | uk.news.yahoo.comPharmaxis teams with renowned surgeon Fiona Wood for scar tissue trialFebruary 1, 2022 | proactiveinvestors.comPharmaxis confident of capturing global market for scar reduction with first patients dosed in studyJanuary 31, 2022 | proactiveinvestors.comPharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatmentsJanuary 6, 2022 | proactiveinvestors.com.auTrade Alert: The Independent Chairman of the Board Of Pharmaxis Ltd (ASX:PXS), Malcolm McComas, Has Just Spent AU$113k Buying 71% More SharesDecember 27, 2021 | finance.yahoo.comPharmaxis’ oversubscribed share purchase plan raises $2.6 millionDecember 20, 2021 | proactiveinvestors.com.auPharmaxis stocks rising with new drugs coming online in 2022, says brokerDecember 6, 2021 | proactiveinvestors.com.auPharmaxis bolsters balance sheet with $7.2 million placement and $2 million share purchase planNovember 17, 2021 | proactiveinvestors.comPharmaxis raising $9.2 million via MorgansNovember 15, 2021 | afr.comFDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver CancerNovember 9, 2021 | finance.yahoo.comPharmaxis receives FDA clearance to progress cancer drug to Phase 2 study in liver cancerNovember 9, 2021 | proactiveinvestors.comPharmaxis receives approval for phase 2 study of its cancer drug in liver cancerNovember 8, 2021 | proactiveinvestors.comPharmaxis attracts A$0.53 price target in coverage initiation from MST AccessNovember 7, 2021 | proactiveinvestors.com Get Pharmaxis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. PXS Media Mentions By Week PXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PXS News Sentiment▼0.000.49▲Average Medical News Sentiment PXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PXS Articles This Week▼00▲PXS Articles Average Week Get Pharmaxis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LTM News Today TEUFF News Today RA News Today IMPPP News Today ENB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PXS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PXS Stock Alerts